相关单倍型相合供体比匹配的无关供体是更好的选择：反对观点。
Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.
作者信息
Shaw Bronwen E
机构信息
Center for International Blood and Marrow Transplant Research, Froedtert & the Medical College of Wisconsin, Milwaukee, WI.
出版信息
Blood Adv. 2017 Feb 14;1(6):401-406. doi: 10.1182/bloodadvances.2016002188.
Abstract
This article has a companion Point by Fuchs. Join in the discussion of these articles at Community Conversations.
摘要
本文有一篇由富克斯撰写的配套观点文章。请在“社区对话”中参与对这些文章的讨论。
相似文献
1
Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.相关单倍型相合供体比匹配的无关供体是更好的选择：反对观点。
Blood Adv. 2017 Feb 14;1(6):401-406. doi: 10.1182/bloodadvances.2016002188.
2
Related haploidentical donors are a better choice than matched unrelated donors: Point.相关的单倍体相合供体比匹配的无关供体是更好的选择：观点。
Blood Adv. 2017 Feb 14;1(6):397-400. doi: 10.1182/bloodadvances.2016002196.
3
ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？反对观点。
Blood Adv. 2017 Mar 28;1(9):573-576. doi: 10.1182/bloodadvances.2016001552.
4
Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.预防血管性血友病（VWD）相关产后出血的抗纤溶治疗：适应证与局限性
Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082.
5
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应成为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):517-521. doi: 10.1182/bloodadvances.2016000117.
6
ATG in allogeneic stem cell transplantation: standard of care in 2017? Point.异基因干细胞移植中的抗胸腺细胞球蛋白：2017年的治疗标准？观点。
Blood Adv. 2017 Mar 28;1(9):569-572. doi: 10.1182/bloodadvances.2016001560.
7
Platelets and hemostasis: a new perspective on an old subject.血小板与止血：一个古老主题的新视角。
Blood Adv. 2016 Nov 22;1(1):5-9. doi: 10.1182/bloodadvances.2016000059. eCollection 2016 Nov 29.
8
Platelets as immune-sensing cells.血小板作为免疫感知细胞。
Blood Adv. 2016 Nov 22;1(1):10-14. doi: 10.1182/bloodadvances.2016000067. eCollection 2016 Nov 29.
9
Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应作为骨髓瘤治疗的终点吗？
Blood Adv. 2017 Mar 14;1(8):522-525. doi: 10.1182/bloodadvances.2017000109.
10
Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.成人急性淋巴细胞白血病的免疫疗法：单克隆抗体的作用
Blood Adv. 2016 Dec 27;1(3):260-264. doi: 10.1182/bloodadvances.2016000042.
引用本文的文献
1
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.移植后环磷酰胺在非血缘骨髓移植受者中的 3 年结果：一项全国骨髓供者计划赞助的前瞻性临床试验的随访。
Transplant Cell Ther. 2023 Mar;29(3):208.e1-208.e6. doi: 10.1016/j.jtct.2022.12.017. Epub 2022 Dec 27.
2
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes.美国造血细胞移植的最新趋势，重点关注青少年和年轻成人的移植活动和结果。
Transplant Cell Ther. 2022 Jul;28(7):409.e1-409.e10. doi: 10.1016/j.jtct.2022.04.012. Epub 2022 Apr 18.
3
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.国家骨髓捐赠者计划-赞助的 HLA 错配无关供者骨髓移植使用移植后环磷酰胺的多中心 II 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1971-1982. doi: 10.1200/JCO.20.03502. Epub 2021 Apr 27.
4
Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults.清髓性单倍体相合 BMT 联合移植后环磷酰胺治疗儿童和成人血液系统恶性肿瘤。
Blood Adv. 2020 Aug 25;4(16):3913-3925. doi: 10.1182/bloodadvances.2020001648.
5
Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation.人类白细胞抗原的分子差异与单倍体相合干细胞移植的结果相关。
Blood Adv. 2020 Aug 11;4(15):3474-3485. doi: 10.1182/bloodadvances.2019000797.
6
Haploidentical transplant in patients with myelodysplastic syndrome.单倍体相合移植治疗骨髓增生异常综合征患者
Blood Adv. 2017 Sep 27;1(22):1876-1883. doi: 10.1182/bloodadvances.2017007146. eCollection 2017 Oct 10.
本文引用的文献
1
How important is NK alloreactivity and KIR in allogeneic transplantation?自然杀伤细胞同种异体反应性和杀伤细胞免疫球蛋白样受体在同种异体移植中有多重要？
Best Pract Res Clin Haematol. 2016 Dec;29(4):351-358. doi: 10.1016/j.beha.2016.10.010. Epub 2016 Oct 20.
2
Selecting the best haploidentical donor.选择最佳的单倍体相合供者。
Semin Hematol. 2016 Oct;53(4):246-251. doi: 10.1053/j.seminhematol.2016.08.001. Epub 2016 Aug 15.
3
Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植中的供者特异性抗HLA抗体
Front Immunol. 2016 Aug 12;7:307. doi: 10.3389/fimmu.2016.00307. eCollection 2016.
4
Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.5 年幸存者中接受骨髓与外周血无关供者移植患者报告结局的比较：一项随机临床试验的长期随访。
JAMA Oncol. 2016 Dec 1;2(12):1583-1589. doi: 10.1001/jamaoncol.2016.2520.
5
Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.非清髓性预处理后单倍体相合供者造血细胞移植中，以骨髓或外周血作为干细胞来源的可比结局：配对分析
Bone Marrow Transplant. 2016 Dec;51(12):1599-1601. doi: 10.1038/bmt.2016.215. Epub 2016 Aug 15.
6
Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML.AML患者接受HLA配型相合与单倍型相合造血细胞移植后给予移植后大剂量环磷酰胺
Bone Marrow Transplant. 2016 Dec;51(12):1561-1564. doi: 10.1038/bmt.2016.217. Epub 2016 Aug 15.
7
Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.单倍体相合或非血缘供者骨髓或造血干细胞移植治疗成年血液系统恶性肿瘤患者后的比较结局
Biol Blood Marrow Transplant. 2016 Nov;22(11):2047-2055. doi: 10.1016/j.bbmt.2016.08.003. Epub 2016 Aug 10.
8
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?我们如何为富含T细胞的HLA单倍型相合移植选择最佳供体？
J Hematol Oncol. 2016 Apr 12;9:35. doi: 10.1186/s13045-016-0265-2.
9
Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation.单倍型相合移植与匹配相关或匹配无关造血细胞移植后的复发后生存率。
Bone Marrow Transplant. 2016 Jul;51(7):949-54. doi: 10.1038/bmt.2016.62. Epub 2016 Mar 21.
10
Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.采用移植后环磷酰胺、他克莫司和霉酚酸酯预防无关供者外周血干细胞移植中的移植物抗宿主病
Biol Blood Marrow Transplant. 2016 Jun;22(6):1037-1042. doi: 10.1016/j.bbmt.2016.03.004. Epub 2016 Mar 10.
Zotero 插件